See What HealthDay Can Do For You
Contact Us

Sessile Serrated Polyps More Common in Women

More than three-quarters of sessile serrated adenomas have BRAF mutations

WEDNESDAY, Nov. 22 (HealthDay News) -- Sessile serrated adenomas are found in 9 percent of colonoscopy patients, and they are more common in female patients and those with multiple polyps, researchers report in the November issue of Gastroenterology. The adenomas are more likely to be found in the proximal colon.

Kevin J. Spring, of Royal Brisbane Hospital in Herston, Australia, and colleagues performed high-magnification chromoendoscopy on 190 colonoscopy patients.

The researchers found polyps in 72 percent of patients, including adenomas (60 percent), hyperplastic polyps (29 percent), sessile serrated adenomas (9 percent), and mixed (1.7 percent). Most adenomas (73 percent) and sessile serrated adenomas (75 percent) were in the proximal colon. A sessile serrated adenoma was linked to multiple polyps and female gender; 78 percent of sessile serrated adenomas had BRAF mutations.

"The prevalence of sessile serrated adenomas is approximately 9 percent in patients undergoing colonoscopy," the authors write. "They are associated with BRAF mutation, proximal location, female sex, and presence of multiple polyps. These findings emphasize the importance of identifying and removing these lesions."

In an editorial, Daniel C. Chung, M.D., of Massachusetts General Hospital in Boston and a colleague note that "until more data are available, it would be prudent to recommend complete resection of sessile serrated adenomas and surveillance examinations."

Abstract
Full Text (subscription or payment may be required)
Editorial

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.